Equillium (EQ) Non-Current Deffered Revenue (2022 - 2023)
Equillium (EQ) posted quarterly Non-Current Deffered Revenue of $2.4 million for Q3 2023, down 59.37% quarter-over-quarter from $6.0 million in Q2 2023.
Powered by 
Analysis
Equillium (EQ) Non-Current Deffered Revenue (2022 - 2023) Analysis & Trends
Equillium (EQ) has reported Non-Current Deffered Revenue for 2 consecutive years, with $2.4 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Non-Current Deffered Revenue changed N/A year-over-year to $2.4 million; the TTM figure through Sep 2023 stood at $2.4 million (changed N/A YoY), while the FY2022 annual figure was $10.4 million, changed N/A from the prior year.
- Non-Current Deffered Revenue retreated to $2.4 million in Q3 2023 per EQ's latest filing, from $6.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $10.4 million in Q4 2022 and bottomed at $2.4 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 2.42 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 7.94 Mn |
| Dec 31, 2022 | 10.38 Mn |